Behçet's disease (BD) is a multisystem inflammatory disorder of uncertain 
origin, although it remains defined within the spectrum of systemic 
immune-mediated vasculitic disorders and also represents a spectrum of putative 
autoimmune disease. Major symptoms include oral aphthous ulcers, genital 
ulcerations, skin lesions, and ocular lesions. Despite afflicting many systems, 
ocular complications of BD are some of the more devastating for the patient and 
their quality of life. Eye involvement, which affects 60-80 % of BD patients, is 
characterized in its more severe form by posterior or panuveitis including 
occlusive retinal vasculitis. While pathogenesis of BD remains complex, 
association with Class I MHC (HLA-B*51) predisposing to inflammation with 
engagement of the innate-immune system (neutrophils, NK cells), and perpetuated 
by the adaptive T cell responses against infectious- and/or auto-antigens. 
Despite the choice of conventional immunosuppressive therapies available, only 
recently with the advent of biologic therapy has visual prognosis and outcomes 
been substantially and favorably altered. For example, both interferon-α (IFN-α) 
and tumour necrosis factor (TNF)-α antagonists deliver promising results and for 
the first time improve prognosis. With IFN-α therapy, durable remissions of 
uveitis can be achieved and lead to drug-free remission. Similarly, anti-TNF 
therapy with infliximab is reported to be rapidly effective in inducing and 
maintaining remission. Most recently, rising evidence reports on the use of 
adalimumab, etanercept, and golimumab, while use of anti-interleukin (IL)-1 
agents (anakinra, canakinumab, gevokizumab), IL-6 blockers (tocilizumab), and 
rituximab (depleting anti-CD20 antibody) is also increasing. The aim of this 
review is to provide evidence for the role of conventional therapies combined 
with evidence for advantages and disadvantages of biologic therapies in the 
treatment of ocular BD. Although randomized controlled trials remain sparse, 
evidence remains strong and enticing that biologic agents are invaluable for the 
treatment of sight-threatening Behçet's uveitis and makes it an exciting time 
for Behçet's specialists worldwide.